Clinical Trial

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).
Protocol Amendment History 4 changes
notable Trial sites expanded: 27 -> 34 locations 2026-04-09
notable Primary completion pushed: 2026-11 -> 2027-11 2026-04-09
minor Completion pushed: 2028-07 -> 2028-12 2026-04-09
notable Trial sites expanded: 17 -> 27 locations 2026-03-31
Trial Details
NCT Number NCT06561048
Lead Sponsor Corvus Pharmaceuticals, Inc.
Conditions Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell
Enrollment 150 participants
Start Date 2024-10-02
Primary Completion 2027-11 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-08